Antibody-Guided Drug Shows Encouraging Activity In Metastatic Breast Cancer

[News]

A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher...

More... (http://www.medicalnewstoday.com/articles/173890.php)